CompletedNot Applicable

A Real-World Study of Omalizumab Treatment Patterns in Chronic Urticaria Patients in China

China3,485 participantsStarted 2026-03-10

Plain-language summary

The aim of this study was to characterize the real-world treatment patterns of omalizumab among adult patients with chronic urticaria in China using data from a regional electronic healthcare (rEHR) database. This included assessing the frequency and proportion of prescriptions across different dosages of omalizumab in real-world clinical practice.

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with at least one diagnosis of chronic urticaria during the study period. A chronic urticaria diagnosis is defined as including "chronic urticaria" but without any rule-out terms in the diagnosis name.
✓. Patients treated with omalizumab during the identification period. The date of first omalizumab prescription is defined as the index date.
✓. Patients aged 18 years or older at index.
✓. Patients with at least one medical record ≥12 months prior to index date.
✓. Patients with at least one medical record ≥12 months post index date.

Exclusion criteria

✕. Patients with a diagnosis of allergic asthma during the study period.
✕. Patients without any dosing information (raw or derived) for omalizumab.

What they're measuring

Average Dose of Omalizumab Per Patient-Year

Timeframe: Up to approximately 2 years and 10 months

Number and Percentage of Omalizumab Prescriptions by Omalizumab Dosage

Timeframe: Up to approximately 2 years and 10 months

Trial details

NCT IDNCT07450170

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-03-23

View on ClinicalTrials.gov More Chronic Urticaria trials